Lorian Capital Corp.
TSX VENTURE : LRN.P

August 15, 2007 14:22 ET

Lorian Capital Corp. Announces Receipt of Conditional Approval for Its Qualifying Transaction From the TSX Venture Exchange

TORONTO, ONTARIO--(Marketwire - Aug. 15, 2007) - Lorian Capital Corp. ("Lorian") (TSX VENTURE:LRN.P), a capital pool company listed on the TSX Venture Exchange (the "Exchange"), announced today that it received conditional approval from the Exchange on August 14, 2007 concerning its previously announced Qualifying Transaction with Medworxx Inc. ("Medworxx"). Details of the proposed Qualifying Transaction can be found in the joint Filing Statement of Lorian and Medworxx filed on SEDAR under Lorian's profile at www.sedar.com. Closing of the transaction, as well as the closing of the concurrent private placement, is expected to occur on or about August 23, 2007, subject to the satisfaction of all closing conditions. Upon the closing of the transaction and the private placement, Lorian anticipates being listed on the Exchange as a Tier 2 Issuer and will recommence trading under the symbol "MWX".

Investors are cautioned that, except as disclosed in filing statement prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

This press release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Lorian and Medworxx to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Examples of such statements include: (i) the intention to complete the transactions; (ii) any description of Lorian that assumes completion of the transactions; and (iii) the intention to grow the business and operations of Lorian or Medworxx. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. Such forward-looking statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to: the ability of Lorian to obtain necessary financing; satisfy the requirements of the Exchange with respect to the closing of the transactions; the economy generally; consumer interest in Lorian's and Medworxx' services and products; competition; and anticipated and unanticipated costs. While Lorian anticipates that subsequent events and developments may cause its views to change, Lorian and Medworxx specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing Lorian's or Medworxx' views as of any date subsequent to the date of this press release. There are many factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The factors identified above are not intended to represent a complete list of the factors that could affect Lorian or Medworxx.

The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the content of this news release. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information